




RealRate

ADVERTISING 2020

US-China Biomedical Technology Inc. Rank 28 of 29





RealRate

ADVERTISING 2020

US-China Biomedical Technology Inc. Rank 28 of 29

The relative strengths and weaknesses of US-China Biomedical Technology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of US-China Biomedical Technology Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 2,920% points. The greatest weakness of US-China Biomedical Technology Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 5,726% points.

The company's Economic Capital Ratio, given in the ranking table, is -6,050%, being 5,295% points below the market average of -756%.

Input Variable	Value in 1000 USD
Assets, Current	58
Assets, Non-Current	0
Cost of Goods and Services Sold	0
General and Administrative Expense	0
Intangible Assets	0
Liabilities, Current	22
Liabilities, Non-Current	0
Marketing and Selling Expenses	0
Other Assets	19
Other Compr. Net Income	0
Other Expenses	0.80
Other Liabilities	54
Other Net Income	-710
Other Revenues	0
Property, Plant and Equipment	0

Output Variable	Value in 1000 USD
Assets	77
Liabilities	76
Expenses	0.80
Revenues	0
Stockholders Equity	1.4
Net Income	-711
Comprehensive Net Income	-711
Economic Capital Ratio	-6,050%